Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Emphasis On Self-Awareness And Personal Will In Groundbreaking 'Reorganizational Healing' Model
Reorganizational Healing (ROH), an emerging concept for wellness, healing, and personal growth, is explored in depth in a seminal groundbreaking article and accompanying commentaries in the latest issue of The Journal of Alternative and Complementary Medicine, a peer-reviewed journal published by Mary Ann Liebert, Inc. The Reorganizational Healing articles are available free online at http://www.liebertpub.com/acm.

Hemophilia A Mice Benefit From Gene Therapy
Hemophilia A is an inherited bleeding disease caused by a lack of the blood clotting protein Factor VIII. It had been hoped that gene therapy would provide a breakthrough in treatment, but the most common gene therapy approach has had little clinical success. However, a team of researchers, at the University of Minnesota Medical School, Minneapolis, has now developed a new approach to target genes specifically to mouse liver sinusoidal endothelial cells (the cells that are the main of Factor VIII) and used it to provide long-term expression of Factor VIII in hemophilia A mice, markedly reducing their disease. They hope that their data might prove to be a step toward successful human clinical trials in individuals with hemophilia A.
News of the day
Only Drop-In Needle Exchange Center In Minnesota Closes Due To Lack Of Funding
Minnesota"s only storefront needle exchange drop-in center, called Access Works!, "fell victim to economic hard times and federal anti-drug policies" and ended its program last week after 13 years, the Minnesota Independent reports. The program "traded used needles for clean ones, conducted HIV and Hepatitis C testing, taught overdose prevention, held support groups and connected users with chemical dependency treatment experts," according to the Independent. Federal funding cannot be used to administer needles for such programs, Lauri Wollner, executive director of the program said. She added, "The federal ban has had a long-term impact. We spend almost $40,000 a year on needles and about $5,000 a year on disposal (of used needles)." Private donations also have been down, she said. While the ban on the use of federal funding for needle exchange is being revisited by Congress, "local needle-exchange activists say it is doubtful that congressional action will be able to save the struggling organization," the article states (Birkey, 8/3).
Health Insurance

Innovative Treatment Approach Offers New Hope For Eczema Sufferers With Moderate To Severe Disease

The British Association of Dermatology annual meeting sees the launch of the first topical calcineurin inhibitor to be approved for the maintenance treatment of moderate to severe atopic eczema to prevent flares and prolong flare-free intervals. PROTOPIC ointment (tacrolimus monohydrate) is already licensed to treat moderate and severe eczema (atopic dermatitis), often involving the treatment of flares as and when they occur.* It is now also approved for twice-weekly application to previously affected skin to prevent these exacerbations and prolong flare-free periods in PROTOPIC-responsive patients. Clinical studies have shown that this new approach brings significant benefits with over 40% of patients with moderate to severe eczema remaining flare-free for at least a year.1 Flares are known to place an enormous burden on patients. The International Study of Life with Atopic Eczema (ISOLATE) found that about 55% of these patients worried about the onset of their next exacerbation and that they spent on average over a third of the year (136 days) with their eczema in flare.2 "Patients should aim to treat the acute flares and try to prevent further ones" said Dr Anthony Abdullah from the Birmingham Skin Centre. He added: "the concept of prevention of exacerbation and maintenance therapy is well understood and utilised in other common and related atopic disorders such as bronchial asthma." The standard approach to managing eczema has been to treat flares as and when they occur with topical anti-inflammatory agents. However, a deeper understanding of the pathology of this disease has revealed that sub-clinical inflammation persists, even after the clinical signs of flare have resolved.3,4 This new twice-weekly treatment regimen with PROTOPIC ointment will allow physicians to actively manage appropriate patients with moderate to severe atopic dermatitis in between flares, in order to prevent flare recurrence and prolong the time that patients are free from flares. * in adults and children ( 2 years) who are unresponsive or intolerant to conventional therapies such as topical corticosteroids in patients who experienced at least four flares per year, who respond to a maximum of six weeks of twice-daily treatment with PROTOPIC Approval of the twice-weekly regimen of PROTOPIC was based on sub-analysis of the results from two phase III studies (CONTROL) conducted in 524 adults and children in 13 European countries, which found that once patients had responded to twice-daily treatment of their flares with PROTOPIC ointment, continuing treatment to previously affected areas with a twice-weekly regimen significantly reduced the number of flares compared to a flare treatment-only regimen.5,6 Patients in the twice-weekly PROTOPIC ointment group also noticed a significant delay in time to first flare (123 vs. 14 days in adults, and 146 vs. 17 days in children), compared to those treated with the standard PROTOPIC treatment regimen.1 Atopic dermatitis is highly prevalent, with approximately one in nine people in England affected by the disease in 2005.7 Research has also shown that around one in five children in England (About PROTOPIC PROTOPIC ointment (tacrolimus monohydrate) has been marketed in Europe for the treatment of moderate to severe atopic dermatitis in adults and children aged two and over since its launch in 2001. This new indication is for maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring four or more times per year) who have had an initial response to a maximum of six weeks treatment of twice-daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected). Discovered and developed by Astellas Pharma Inc., PROTOPIC has been marketed in 45 countries worldwide, including Japan, the US, and countries in Europe, Asia and Latin America. References 1. PROTOPIC Summary of Product Characteristics. 2009 2. Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006;11:226-232 3. Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest 2004;113:651-7 4. Wollenberg A and Bieber T. Proactive therapy of atopic dermatitis - an emerging concept. Allergy 2009;64:276-278 5. Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008;63:742-750 6. Thaӧi D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Brit J Dermatol 2008;159:1348-56 7. Simpson CR, Newton J, Hippisley-Cox J, et al. Trends in the epidemiology and prescribing of medication for eczema in England. J R Soc Med 2009;102;108-117 8. Bieber T. Mechanisms of disease: atopic dermatitis. N Engl J Med 2008;358:1483-1494 Astellas UK


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

Copyright 2009